Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.
By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines ...
Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new ...
Gilead Sciences has experienced a significant valuation re-rating, now trading at 16-17x earnings after doubling from 2024 lows. Read why GILD stock is a hold.
Zacks Investment Research on MSN
Is Gilead (GILD) a buy as Wall Street analysts look optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course.
Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...
Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs ...
Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years ...
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro MedicinesNew partnership structure ...
Gilead makes one of its biggest bets yet After fat-fighting results, this startup looks for more funding After fat-fighting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results